TM Capital

JULY 17, 2024

Josh Mastracci has joined TM Capital as a Director in the firm’s Healthcare practice. Josh has extensive experience completing transactions across key healthcare services sectors including physician practice management, ambulatory surgery centers, and pharmaceutical services. Josh holds a B.A. in Economics from Boston College, a J.D.

Capital 52

Capital Pharmaceutical Private Equity Healthcare 52

Cooley M&A

OCTOBER 19, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 2019 was a banner year for billion-dollar life sciences M&A transactions.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

DECEMBER 20, 2024

While Retina groups were already receiving competitive valuations from private equity-backed companies like EyeSouth Partners and NVision Eye Centers, the RCA-Cencora transaction indicates there are long-term buyers outside of private equity for retina practices with the capital to acquire and operate them.

Private Equity 52

Private Equity Healthcare Equities Sale 52